Association of Gut Microbiome Dynamics With Systemic Inflammation and Disease‐Free Survival in Osteosarcoma Patients
7 affiliations
- 1Department of Biomedical and Neuromotor Sciences University of Bologna Bologna Italy
- 2Unit of Microbiome Science and Biotechnology, Department of Pharmacy and Biotechnology University of Bologna Bologna Italy
- 3Biomedical Science and Technologies and Nanotechnology Lab IRCSS Istituto Ortopedico Rizzoli Bologna Italy
- 4Osteoncologia, Sarcomi Ossei e Dei Tessuti Molli e Terapie Innovative IRCCS Istituto Ortopedico Rizzoli Bologna Italy
- 5Department of Orthopaedic Oncology IRCCS Istituto Ortopedico Rizzoli Bologna Italy
- 6Human Microbiomics Unit, Department of Medical and Surgical Sciences University of Bologna Bologna Italy
- 7IRCCS Azienda Ospedaliero‐Universitaria di Bologna Bologna Italy
Abstract
Gut microbiota (GM) is increasingly recognised as a key modulator of cancer development, progression, and treatment response. However, clinical studies remain limited, especially in osteosarcoma (OS), the most common bone cancer in children and adolescents. In this study, we analysed GM diversity, composition, and predicted function in a small OS cohort (n = 18) using 16S rRNA gene sequencing of stool samples collected at diagnosis, during chemotherapy, and post‐treatment. Microbial profiles were compared to healthy controls. Alpha diversity was assessed via ASVs, Shannon, inverse Simpson, and Faith's index; beta diversity via Bray‐Curtis and UniFrac distances. We examined associations between GM profiles and clinical variables (age, gender, BMI, tumour volume, outcome) and systemic inflammation (e.g., C‐reactive protein, CRP) using PERMANOVA, LEfSe, and Kaplan–Meier analysis. At diagnosis, OS patients showed reduced diversity and a distinct GM signature—depletion of anti‐inflammatory genera (Blautia, Faecalibacterium, Roseburia) and enrichment of potentially pro‐tumorigenic taxa (Collinsella, Streptococcus), which correlated with elevated CRP. Baseline GM composition stratified patients by long‐term outcome, with specific taxa and predicted pathways linked to event‐free survival. Chemotherapy induced transient dysbiosis, notably affecting Lactobacillus and Enterococcus, with partial recovery post‐treatment. This is the first study to track GM alterations in OS patients across the disease course, extending current knowledge beyond preclinical models. As one of the few longitudinal microbiota studies in oncology, it highlights GM's potential as a biomarker, shedding light on the mechanisms underlying OS pathogenesis, though findings require validation in larger cohorts.
Related
- Impact of YAQ001 on the Gut Microbiome, Permeability and Markers of Systemic Inflammation in Patients With Cirrhosis.
- Heart Failure and Risk Assessment in Systemic Autoimmune Disease: Do Inflammation, Autoantibodies and Sex Matter?
- Linking systemic inflammation nutrition status to the tumor immune microenvironment: integrated biomarkers of neoadjuvant response in locally advanced rectal cancer
- From systemic to oral: Unifying immunological mechanisms via the gut microbiome axis
- The Oral–Gut–Systemic Axis in Periodontitis: Microbiome Dysbiosis, Immune Crosstalk and Translational Perspectives
BibTeX
@article{avnet2026association,
title = {{Association of Gut Microbiome Dynamics With Systemic Inflammation and Disease‐Free Survival in Osteosarcoma Patients}},
author = {Sofia Avnet and Federica D'Amico and Luigi Falzetti and Gemma Di Pompo and Alessandro Pasquarelli and Alessandra Longhi and Costantino Errani and Patrizia Brigidi and Silvia Turroni and Nicola Baldini},
journal = {Cancer Medicine},
year = {2026},
month = nov,
doi = {10.1002/cam4.72399},
url = {https://doi.org/10.1002/cam4.72399},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Association of Gut Microbiome Dynamics With Systemic Inflammation and Disease‐Free Survival in Osteosarcoma Patients
AU - Sofia Avnet
AU - Federica D'Amico
AU - Luigi Falzetti
AU - Gemma Di Pompo
AU - Alessandro Pasquarelli
AU - Alessandra Longhi
AU - Costantino Errani
AU - Patrizia Brigidi
AU - Silvia Turroni
AU - Nicola Baldini
PY - 2026
DA - 2026/11/11
JO - Cancer Medicine
DO - 10.1002/cam4.72399
UR - https://doi.org/10.1002/cam4.72399
AB - Gut microbiota (GM) is increasingly recognised as a key modulator of cancer development, progression, and treatment response. However, clinical studies remain limited, especially in osteosarcoma (OS), the most common bone cancer in children and adolescents. In this study, we analysed GM diversity, composition, and predicted function in a small OS cohort (n = 18) using 16S rRNA gene sequencing of stool samples collected at diagnosis, during chemotherapy, and post‐treatment. Microbial profiles were compared to healthy controls. Alpha diversity was assessed via ASVs, Shannon, inverse Simpson, and Faith's index; beta diversity via Bray‐Curtis and UniFrac distances. We examined associations between GM profiles and clinical variables (age, gender, BMI, tumour volume, outcome) and systemic inflammation (e.g., C‐reactive protein, CRP) using PERMANOVA, LEfSe, and Kaplan–Meier analysis. At diagnosis, OS patients showed reduced diversity and a distinct GM signature—depletion of anti‐inflammatory genera (Blautia, Faecalibacterium, Roseburia) and enrichment of potentially pro‐tumorigenic taxa (Collinsella, Streptococcus), which correlated with elevated CRP. Baseline GM composition stratified patients by long‐term outcome, with specific taxa and predicted pathways linked to event‐free survival. Chemotherapy induced transient dysbiosis, notably affecting Lactobacillus and Enterococcus, with partial recovery post‐treatment. This is the first study to track GM alterations in OS patients across the disease course, extending current knowledge beyond preclinical models. As one of the few longitudinal microbiota studies in oncology, it highlights GM's potential as a biomarker, shedding light on the mechanisms underlying OS pathogenesis, though findings require validation in larger cohorts.
SN - 2045-7634
ER -